Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance upgrade on Thursday 4th of May 2017 from 8.00am to 9.00am (BST).

During this time our websites will be offline temporarily. If you have any questions please use the feedback button on this page. We apologise for any inconvenience this might cause and thank you for your patience.



Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer

Author affiliations

Abstract

A phospholipid-mimic oxaliplatin prodrug (Oxalipid) was synthesized, which could self-assemble into a liposomal nanostructure with a drug loading ratio as high as 27 wt%. Compared to free oxaliplatin, the resulting Oxalipid liposome displayed elongated blood circulation, increased tumor accumulation and improved anticancer efficacy against the metastatic triple negative breast cancer (TNBC).

Graphical abstract: Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer

Back to tab navigation
Please wait while Download options loads

Supplementary files

Publication details

The article was received on 19 Jan 2017, accepted on 31 Mar 2017 and first published on 31 Mar 2017


Article type: Communication
DOI: 10.1039/C7BM00058H
Citation: Biomater. Sci., 2017, Advance Article
  •   Request permissions

    Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer

    B. Feng, F. Zhou, W. Lu, D. Wang, T. Wang, C. Luo, H. Wang, Y. Li and H. Yu, Biomater. Sci., 2017, Advance Article , DOI: 10.1039/C7BM00058H

Search articles by author